Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer

Yu, Weiwei; Guo, Yan‐Mei

doi:10.1097/md.0000000000011614

Cited by 17 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor grade was determined in 97 patients, 39.2% of which were high grade ( Table 1). Most patients (73%-63%) received postoperative radiotherapy.…”

Section: Resultsmentioning

confidence: 99%

Prognostic markers in salivary gland cancer and their impact on survival

et al. 2019

View full text Add to dashboard Cite

Background The role of molecular markers in salivary gland carcinoma (SGC) is not well understood. We evaluated molecular marker expression and their prognostic value. Methods Immunohistochemical analysis of 124 tumor specimens was performed to determine expression of androgen (AR), estrogen (ER), and progesterone (PR) receptors and epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), programmed death ligand 1 receptor (PD‐L1), and PD‐L1 in tumor‐infiltrating mononuclear cell (TIMC). Survival outcomes (disease‐free survival [DFS] and overall survival [OS]), pT and N classification, margin status, and treatment failure were assessed. Results Most patients (78; 62.9%) had early‐stage SGC. AR positivity and EGFR positivity were detected in 21.0% and 78.6%, respectively, of tumors. AR positivity and PD‐L1 negativity were associated with locally advanced disease. PD‐L1‐negativity was associated with higher recurrence (38.5% vs 0%; P < .001) and worse DFS. OS and DFS were worse in patients with AR+ or HER2+ disease. Conclusions Several molecular markers—AR and HER2 positivity and PD‐L1 negativity—were associated with worse clinical outcomes. Prospective, multi‐institutional trials are needed to determine the prognostic value of these markers.

show abstract

“…The tumor grade was determined in 97 patients, 39.2% of which were high grade ( Table 1). Most patients (73%-63%) received postoperative radiotherapy.…”

Section: Resultsmentioning

confidence: 99%

Prognostic markers in salivary gland cancer and their impact on survival

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The quality of the enrolled studies was independently assessed based on the Newcastle-Ottawa Scale (NOS) score. [23] In the NOS system, a score >6 was considered high quality.…”

Section: Methodsmentioning

confidence: 99%

Tiam1 high expression is associated with poor prognosis in solid cancers

Ding

Yang²,

Wang³

2019

Medicine

View full text Add to dashboard Cite

Background: A number of studies have attempted to determine the prognostic value of T-cell lymphoma invasion and metastasis-inducing factor 1 (Tiam1) in patients with solid cancers, but the reported results were of inconsistency. Thus, we performed a systematic review and meta-analysis to exhaustively evaluate the prognostic role of Tiam1 expression in patients with solid cancers.Methods: We retrieved literature published in between 1994 and April 22th, 2019 through searching PubMed, Web of Science and China national knowledge infrastructure (CNKI). Hazard ratios (HRs) coupled with 95% confidence intervals (95% CIs) were used to assess the relationship of Tiam1 expression and overall survival (OS), and disease-free survival (DFS).Results: A total of 2647 patients with solid cancers in 20 studies were enrolled in our meta-analysis eventually. The pooled results showed that Tiam1 high expression was closely correlated with poor OS (HR = 2.17, 95% CI: 1.80–2.61, P = .000) and DFS (pooled HR = 1.95, 95% CI = 1.58–2.40, P = .000). Moreover, our subgroup analysis and sensitivity analysis demonstrated the reliability and stability of our pooled results.Conclusion: In conclusion, this meta-analysis confirmed that Tiam1 higher expression positively correlated with OS and DFS, suggesting that Tiam1 may act as a valuable prognostic predictor and therapeutic target for patients with solid cancers. Nevertheless, in future more homogeneous and prospective studies should be performed to further support our findings.

show abstract

“…They also performed a subgroup analysis according to histology-in patients with ESCC, the combined hazard ratio confirmed PD-L1 overexpression to be a poor prognostic index of OS. Due to the limited number of included studies involving EAC, no evidence about this histology could be stated [53]. In another series of 150 ESCC, the over-expression of PD-L1 and PD-L2 rated around 64% and 42%, respectively, with a significant correlation between the expression of both.…”

Section: Pd-l1 Expressionmentioning

confidence: 98%

Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?

Vivaldi

Catanese

Massa

et al. 2020

IJMS

View full text Add to dashboard Cite

Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignancies, such as non-small cell lung cancer and melanoma. Recent clinical trials also showed promising activity in immune checkpoint inhibitors in pretreated advanced esophageal carcinoma and a potentially significant impact on the outcome of selected patients, independently of histology. Combination studies evaluating immunotherapy and chemotherapy and, in localized disease, radiotherapy are in progress and will hopefully confirm their promises in the near future. However, reliable predictive biomarkers are still lacking. Indeed, at present, the role of programmed cell death ligand 1 expression and other factors (such as microsatellite instability and tumor mutational burden) as predictive biomarkers of benefit to immune checkpoint inhibitors is still controversial. Our aim was to explore the rationale of ICIs in esophageal cancer, review the results already available in multiple settings, and investigate future perspectives with single-agent and combination strategies.

show abstract

Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer

Cited by 17 publications

References 32 publications

Prognostic markers in salivary gland cancer and their impact on survival

Prognostic markers in salivary gland cancer and their impact on survival

Tiam1 high expression is associated with poor prognosis in solid cancers

Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?

Contact Info

Product

Resources

About